Ilenia Calcaterra: Innovation In Rare Diseases Is Never Abstract
Ilenia Calcaterra, Consultant Physician in Internal Medicine and Assistant Professor at the University of Naples Federico II, shared on LinkedIn, adding:
”Today is Rare Disease Day.
I work actively in the field of rare diseases, where progress often depends on rigorous research, multidisciplinary collaboration, and responsible clinical decision-making.
This image captures a milestone in our clinical practice: in September 2024, we administered the first gene therapy for Hemophilia A in our center.
Innovation in rare diseases is never abstract.
It is built carefully, through evidence, integrity, and high standards especially when patient numbers are small and every decision carries weight.
Raising awareness matters.
Building reliable evidence matters even more.
In rare diseases, small numbers require higher standards not lower ones.”
Stay updated with Hemostasis Today.
-
Nov 5, 2026, 18:57Maria Luszczyn: Does Blood Transfusion Really Worsen Long-Term Survival after CABG or is Preoperative Anemia the Main Driver?
-
Nov 5, 2026, 18:20Jessica Vega: How Listening to Patient Experience Reframes Warm Autoimmune Hemolytic Anemia Care
-
Nov 5, 2026, 18:15Paresh P Kulkarni: Frontiers in Immunology Launches Call for Papers on Innate Immune Mechanisms and Biomarkers in APS
-
Nov 5, 2026, 18:08Perrine Henry: Iliac Venous Thrombus Identified as Rare Cause of Hindlimb Lameness in Dog with Primary Erythrocytosis
-
Nov 5, 2026, 18:02Kellie Machlus: Bone Marrow Megakaryocytes Present Antigens and Regulate T Cells
-
Nov 5, 2026, 14:42Matteo Foschi: ASPERA-R Reveals the Challenges of Anticoagulation Resumption After Hemorrhagic Transformation
-
Nov 5, 2026, 14:30Khaled Musallam: Assessing the State of Thalassaemia and Sickle Cell Disease Care Across Europe
-
Nov 5, 2026, 14:17Joshua Muia: The Evolution of ADAMTS13 Research
-
Nov 5, 2026, 14:02Paulo Colimodio: Scientific Highlights from the XVII Argentine Congress of Hemostasis and Thrombosis